Latest news with #Drugs
New Indian Express
a day ago
- New Indian Express
Andhra Pradesh CM Chandrababu Naidu leads campaign against drugs
GUNTUR: In a decisive move to combat drug abuse, Chief Minister Nara Chandrababu Naidu on Thursday launched a full-scale campaign against ganja and narcotics, vowing to make Andhra Pradesh a drug-free State. Marking the International Day Against Drug Abuse and Illicit Trafficking, scores of students, government employees, and people rallied behind the slogan 'No Drugs Bro', symbolising a united front in the fight against substance abuse. Naidu joined citizens and students on a walkathon in Guntur, from Fever Hospital Junction to Mirchi Dhaba. Holding banners and chanting slogans, participants pledged their support for a drug-free society. Addressing the gathering after the rally, the Chief Minister underlined the government's firm stance: 'We will not tolerate drugs in any form. Those who sell ganja or narcotics will face strict action, including property confiscation.' As part of its intensified crackdown on drug abuse, the State government announced it will confiscate the properties of individuals involved in the cultivation, transportation, or sale of drugs. To encourage public participation, dedicated citizen-reporting channels have been introduced, including a WhatsApp helpline (8977781972) and a toll-free number (1972), enabling people to report drug-related activities while maintaining anonymity. The State government is also expanding its rehabilitation infrastructure with the establishment of 56 new de-addiction centres, including three of world-class standard. Additionally, fast-track courts for NDPS cases are being set up in key cities such as Visakhapatnam, Rajamahendravaram, Guntur, and Tirupati. To promote long-term awareness and prevention, schools will launch 'Eagle Clubs', while celebrities and influencers are being urged to actively participate in anti-drug campaigns. The State government will also leverage technology, deploying drones and extensive CCTV networks, to monitor and curb drug-related activities more effectively.
Gulf Insider
2 days ago
- Health
- Gulf Insider
Major Achievements: UAE Ministry Of Interior Reports Seizure Of Over 12 Tonnes Of Drugs
The UAE Ministry of Interior has reported significant accomplishments in the country's anti-narcotics efforts for 2024, highlighting robust measures taken to combat drug-related crimes and safeguard public health and safety. Amal Ahmed Al Zeyoudi, Head of Statistics and Studies at the Federal General Directorate for Drug Control at the Ministry of Interior, stated that 2024 witnessed intensified nationwide operations yielding tangible results. 'A total of 9,774 reports related to drug crimes were recorded, involving 13,513 suspects,' she revealed. 'In total, 12,340 kilograms of narcotic substances and psychotropic drugs were seized throughout the year.' Al Zeyoudi also emphasized the UAE's strong commitment to international cooperation in the fight against drugs, noting that joint operations with more than 24 countries led to the seizure of an additional 3,383 kilograms of narcotics outside the UAE. In November 2024, the UAE adopted the National Anti-Narcotics Strategy 2024–2031, which envisions a drug-free nation by 2031. The strategy sets ambitious national targets, including reducing drug-related mortality rates per million people and lowering the prevalence of drug abuse per 100,000 residents. A report issued by the Ministry's Federal Drug Control Directorate noted that the Ministry's integrated efforts have helped curb both supply and demand. A key initiative was launched to assess the spread of narcotics across the country, benchmarking global best practices. Furthermore, a digital platform was developed in collaboration with the healthcare sector to monitor the dispensation of controlled medications and limit their misuse. The Ministry underscored its firm commitment to drug control, providing law enforcement agencies with extensive human, technical, and material resources. Coordination with national, regional, and international entities has been a cornerstone of the strategy. The cornerstone of the UAE's legal framework in this domain is Federal Decree Law No. (30) of 2021 on Narcotic Drugs and Psychotropic Substances, as amended by Federal Decree Law No. (53) of 2022. This legislation adopts a comprehensive approach that balances stringent penalties with pathways for rehabilitation. While the law imposes hefty fines and prison terms depending on the nature and frequency of offenses, it also allows courts to refer individuals to rehabilitation centers instead of incarceration, with close follow-up on treatment progress. The law also calls for active international cooperation to combat drug trafficking and prosecute those involved. In a testament to the UAE's proactive role on the global stage, the Ministry of Interior was elected in April 2025 to the United Nations Commission on Narcotic Drugs (CND) for the term 2026–2029, representing the Asia-Pacific Group. The CND is a central policymaking body within the UN system responsible for overseeing international drug control treaties and guiding global drug policies. The election took place during a vote at the UN Headquarters in New York.
Medscape
13-06-2025
- Health
- Medscape
Diversity Gap Persists in Key Trials for Psoriatic Arthritis
An analysis of 29 pivotal drug trials for psoriatic arthritis revealed significant racial disparities, with White individuals making up the majority of trial participants, whereas Asian, Black, and other racial groups remained underrepresented. Geographic disparities in participant inclusion were also observed, with trial sites primarily located in North America and Europe. METHODOLOGY: Researchers conducted a descriptive epidemiologic study to assess the gaps in reporting of racial, ethnic, and geographic data of participants enrolled in pivotal US clinical trials of biologic and targeted synthetic disease-modifying antirheumatic drugs for psoriatic arthritis. They collected data on 14,845 participants enrolled in 29 trials with start dates from April 2000 to April 2019, using three primary public sources: Journal publications, the Drugs@FDA database, and Overall, 16 drugs with varying mechanisms were assessed in these trials: Seven trials each of TNF inhibitors and interleukin 17A or 17A/F inhibitors, four trials each of JAK inhibitors and interleukin 23 inhibitors, three trials of phosphodiesterase 4 inhibitors, and two trials each of cytotoxic T-lymphocyte antigen immunoglobulin and interleukin 12/23 inhibitors. TAKEAWAY: Data on race were reported in 93% of trials, with the most frequent reporting in journal publications (86%), although 46% of them reported the proportion of only White participants. Among participants for whom data on race were available, 92% were White, 5% were Asian, 0.6% were Black, 0.3% were American Indian/Alaska Native, and 0.1% were Native Hawaiian/Pacific Islander individuals. Ethnicity was formally reported in only 41% of trials. The reporting of both race and ethnicity improved over time, reaching full coverage (eight of eight trials) on between 2016 and 2020. Among participants for whom data on ethnicity were available, 11% were Hispanic or Latino individuals. Within the US, the highest participation was reported from Texas (24 trials), Florida and Pennsylvania (22 each), California (20), and Alabama (18), with participation in clinical trials strongly correlated with state population size (correlation coefficient, 0.78; P < .0001). Trial sites were primarily located in North America and Europe, with limited representation in Asia, Africa, and Latin America. IN PRACTICE: 'Standardizing and mandating race and ethnicity reporting across data sources is crucial to ensure transparency and equity. Tailored and multifaceted recruitment strategies are essential to increase diversity and ensure the generalizability of trial results, ultimately aiding clinicians to provide the most effective and informed treatment options for all patients,' the authors wrote. SOURCE: This study was led by Mathieu Choufani, MD, Brigham and Women's Hospital, Boston. It was published online on May 19, 2025, in Arthritis Care & Research . LIMITATIONS: This study relied on the US-centric Office of Management and Budget categories for data on race and ethnicity, which may not have represented international populations. Definitions of categories were inconsistent across data sources. Site-level enrollment details were lacking. The analysis was focused solely on pivotal trials for FDA-approved drugs. DISCLOSURES: This study had no specific outside funding source. One author reported receiving consulting fees and grants from various pharmaceutical organizations and being a member of the board of directors for the Spondyloarthritis Research and Treatment Network. Another author reported owning stocks in UCB and Abcuro.
Yahoo
10-06-2025
- Business
- Yahoo
Protein Drugs Analysis Report 2025-2029: Therapeutic Proteins Gain Traction for Targeted, Low-Toxicity Treatments, Competitive Landscape Intensifies as Leading Firms Expand Investments
The Protein Drugs Market, valued at USD 441.7 billion in 2024, is set to reach USD 655.7 billion by 2029, growing at an 8.2% CAGR. The report covers market trends, technologies, regional insights, and company profiles, highlighting the rise of recombinant protein drugs for treating diseases like cancer and diabetes. Protein Drugs Market Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Protein Drugs Market 2025" report has been added to Protein Drugs Market was valued at USD 441.7 Billion in 2024, and is projected to reach USD 655.7 Billion by 2029, rising at a CAGR of 8.2% The report analyzes trends in the global market for protein drugs and manufacturing technologies. The report includes global revenue ($ millions) for the base year of 2023 and estimated data for the forecast period of 2024 through 2029. The market is segmented by product type/subtype, manufacturing technology and region. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions. Therapeutic proteins are a class of medicines that help treat a number of indications, such as cancer, diabetes, stroke, anemia and hemophilia. Protein drugs perform particular and complex functions compared to small molecules. Due to the high specificity, these protein drugs are less toxic and less likely to interfere with normal biological processes. Protein drugs can be manufactured in many ways, but most proteins are produced through recombinant deoxyribonucleic acid (rDNA) technology, using bacteria, yeast or mammalian cells as the host report focuses on the trends and challenges that affect the market and the vendor landscape. It analyzes environmental, social, and corporate governance (ESG) developments and discusses patents and emerging technologies related to the market. The report concludes with an analysis of the competitive landscape, which provides the rankings and market shares of leading companies in the protein drug market. It also has a section of company profiles that shows financials, product portfolios and recent report includes: 79 data tables and 57 additional tables An analysis of the global markets for protein drugs and their manufacturing technologies Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029 Estimates of the size of and revenue prospects for the global market, along with a market share analysis by type of protein drug, manufacturing technology, and region Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Analysis of the advances in manufacturing technologies, disease prevalence trends, new products, and the impact of biosimilars entering the market for protein drugs An analysis of patents and significant patent grants Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of leading companies, including: AbbVie Inc., Bristol Myer Squibb, Merck & Co., Novo Nordisk S/A, Sanofi, and Roche Key Attributes: Report Attribute Details No. of Pages 162 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $441.7 Billion Forecasted Market Value (USD) by 2029 $655.7 Billion Compound Annual Growth Rate 8.2% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Current and Future Market Overview Technology Background Pharmacological Classification of Therapeutic Proteins Protein Therapeutics with Enzymatic or Regulatory Activity Protein Therapeutics with Special Targeting Activity Protein Vaccines Characteristics of Therapeutic Proteins Macroeconomic Factors Porter's Five Forces Analysis Supply Chain Analysis R&D Manufacturing Packaging Wholesale Distributors and Repackagers Pharmacies/Hospitals Dispensed to Consumers Chapter 3 Market Dynamics Global Market Dynamics Market Drivers Advances in Manufacturing Technologies Continuous Product Launches Increasing Incidence of Cancer Market Restraints High Costs of Protein Drugs Complex Regulatory Procedures Market Challenges Patent Expiration and Loss of Exclusivity Protein Drugs Stability and Delivery Market Opportunities Increasing Number of Approvals for MAbs Licensing and Collaboration Agreements Chapter 4 Regulatory Landscape Regulatory Scenario Price Regulations Chapter 5 Emerging Technologies Overview Emerging Technologies in Protein Drugs Market Bispecific Antibodies and Multi-Specific Antibodies Antibody-Drug Conjugates Antibody Fusion Proteins AI in the Protein Drug Market Chapter 6 Market Segment Analysis Overview Segmentation Breakdown Global Market for Protein Drugs, by Type MAbs Peptide Hormones Vaccines Blood Factors Cytokines Therapeutic Enzymes Peptide Antibiotics Fusion Proteins Global Market for Protein Drugs, by Manufacturing Technology Cell Culture Microbial Fermentation Natural Source Embryonated Egg Chemical Synthesis Transgenics Market Breakdown by Region Global Market for Protein Drugs, by Region North America Europe Asia-Pacific Rest of the World Chapter 7 Competitive Intelligence Industry Structure Leading Protein Drugs, 2023 Market Share Analysis MAbs Peptide Hormones Strategic Analysis Acquisitions Product Approvals Agreements and Partnerships Other Strategies Chapter 8 Sustainability in the Protein Drug Market: ESG Perspective Sustainability in the Protein Drug Industry ESG Risk Ratings: Understanding the Data ESG Performance Analysis Environmental Performance Social Performance Governance Performance Concluding Remarks Companies Featured AbbVie Inc. Amgen Inc. Astrazeneca Bayer AG Bristol-Myers Squibb Co. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Novartis AG Novo Nordisk A/S Pfizer Inc. Regeneron Pharmaceuticals Inc. Sanofi Takeda Pharmaceutical Co. Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Protein Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
08-06-2025
- Health
- Yahoo
Three Big Medical Costs That Retirees Often Underestimate
Drugs, remote locations and concierge care can add tens of thousands of dollars to healthcare costs in retirement.
